Navigation Links
Wearable Artificial Kidney Passes Test
Date:12/14/2007

8 end-stage kidney failure patients used the device for up to 8 hours, researchers say

FRIDAY, Dec. 14 (HealthDay News) -- The first version of an American-designed wearable artificial kidney has delivered promising results in a pilot trial, British physicians report.

Five men and three women newly diagnosed with end-stage kidney failure used the device for between four and eight hours, according to a report in the Dec. 15 issue of the journal The Lancet.

The device resembles a large tool-belt hung with a variety of devices needed for the dialysis process. Using miniaturized components, it produced satisfactory, if small, rates of blood flow and clearance of toxins from the body, the report said.

That slow rate actually offers an advantage over standard dialysis, said Dr. Garabed Eknoyan, professor of medicine at Baylor College of Medicine, who wrote an accompanying editorial.

Dialysis now is done in three- or four-hour sessions, three times a week, Eknoyan said. "There are two major problems," he said. "The changes occur fast, and removal occurs very fast, before the body gets a chance to accommodate, so there is discomfort with the process. If you dialyse at a lower rate for a longer period, the patient does better."

But dialyzing at a slower rate using a standard artificial kidney has major disadvantages, Eknoyan said. "The patient is tied down to the machine," he said. "Not every patient is willing to cope with that."

The new device was designed by Dr. Victor Gura, a nephrologist at the University of California, Los Angeles. He is chief medical officer of Xcorporeal Inc., the company that made the device.

The discomfort and inefficiency of current dialysis treatment is becoming a bigger issue every years, said Dr. William Henry Fissell, director of the Cleveland Clinic Center for Extracorporeal Therapy.

"The population of patients requiring dialysis has been growing by 8 percent a year for a quarter-century," Fissell said. "The United States now has 400,000 patients on maintenance dialysis."

That increase is due to the growing ability of physicians to prolong the lives of people with the various aliments associated with cardiovascular risk factors such as diabetes and obesity, he said. Kept alive, many of those people will eventually develop kidney failure, Fissell said, and they often find current dialysis therapy unsatisfactory.

An informal network of kidney experts is working to develop better dialysis technology, and the new device is one example of the effort, Fissell said.

Major tests lie ahead, Eknoyan said. "Now that it has passed this stage of trial, we must go to the stage where people use it several times a day," he said. "It remains to be seen how it is going to work. But the evidence is there, and the need is there that people need to dialyze more frequently."

More information

There's more on kidney failure and dialysis at the U.S. National Library of Medicine.



SOURCES: Garabed Eknoyan, M.D., professor, medicine, Baylor College of Medicine, Houston; William Henry Fissell, M.D., director, Cleveland Clinic Center for Extracorporeal Therapy; Dec. 15, 2007 The Lancet


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Herbal Water Creating Taste Sensation: Ayalas Herbal Water Has No Calories, No Preservatives and No Artificial Additives. Just All the Natural Benefits of Herbs!
2. Brain measurements could lead to better devices to move injured or artificial limbs
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. Expenses Overshadow Optimism for Kidney Failure Patients
5. Katie Lee Joel to Conduct Cooking Demonstration for Local Patients With Chronic Kidney Disease
6. Experimental drug shows promise in advanced kidney cancer
7. New Kidney Disease Can Be Fatal
8. Lowering Blood Protein Wont Help Kidney Patients
9. DaVita Teammates Bicycling 230 Miles for Kidney Disease Education
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. Metabolic syndrome heightens risk for development of uric-acid kidney stones
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Wearable Artificial Kidney Passes Test
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... 08, 2016 , ... Healthcare is in flux. The GOP ... the mass media launching of story movements to highlight what's most unfair about ... experiences; such a movement can generate the network power to improve healthcare policies ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016   TriNetX , the health research ... signed a membership agreement to join the ... new cures. The TriNetX network is ... patients globally, biopharmaceutical companies and contract research organizations ... design, site selection, patient recruitment, and collaborative research ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... 8, 2016  EIP Pharma, LLC ( www.eippharma.com ... for neflamapimod (previously code named VX-745), with the ... trials that demonstrated significant Alzheimer,s disease relevant pharmacological ... and Study 303 (6-week treatment) are the subject ... Disease (CTAD) scientific conference in San ...
Breaking Medicine Technology: